Treatment with liraglutide improved measures of pulmonary function in patients suffering from obesity and COPD, according to trials at different hospitals in Denmark. Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus, also exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels, the study found. The controlled, double-blind trials analysed 40 people with obesity and COPD through pulmonary-function tests, 6-min walking test, and with a questionnaire regarding the clinical impact of COPD. It found that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD. Forty weeks of treatment with the GLP-1RA liraglutide improved FVC, DLCO, and the CAT-score in patients.